Clinical Trial Update: Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of inhaled Alpha-1 HC (alpha-1 proteinase inhibitor) in cystic fibrosis; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Alpha-1 HC (alpha-1 proteinase inhibitor (hydrophobic chromatography process))

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2016-02-08